Cargando…
Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study
OBJECTIVES: The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms. METHODS: A nonrandomized comparative case series study was performed. Six patients re...
Autores principales: | Li, Yuping, Shi, Keqing, Qi, Feng, Yu, Zhijie, Chen, Chengshui, Pan, Jingye, Wu, Gaojun, Chen, Yanfang, Li, Ji, Chen, Yongping, Zhou, Tieli, Li, Xiaokun, Xia, Jinglin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834521/ https://www.ncbi.nlm.nih.gov/pubmed/33333254 http://dx.doi.org/10.1016/j.ijid.2020.12.023 |
Ejemplares similares
-
Thalidomide combined with low‐dose short‐term glucocorticoid in the treatment of critical Coronavirus Disease 2019
por: Chen, Chengshui, et al.
Publicado: (2020) -
High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis
por: Xue, Hong-xia, et al.
Publicado: (2015) -
Is the Low-Thalidomide Dose MPT Regimen Beneficial?
por: Min, Chang-Ki
Publicado: (2011) -
High-dose intravenous glucocorticoid induces hyperamylasemia: a case series
por: Yang, Di, et al.
Publicado: (2022) -
Thalidomide and discoid lupus erythematosus: case series and review of literature
por: Malara, Giovanna, et al.
Publicado: (2022)